drugset
drugset / Trial / NCT03384290

Study of a Single Dose of PRS-060 Administered by Oral Inhalation or IV Infusion in Healthy Subjects

NCT03384290 ↗

Phase 1 Completed 72 enrolled Pieris Australia Pty Ltd
RandomizedParallel-groupSingle-blindTreatment

Summary

A Dose Escalating Study of PRS-060 Administered by Oral Inhalation or IV Infusion in Healthy Subjects

Timeline

Start
2017-12-08
Primary completion
2018-10-11
Completion
2018-10-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Elarekibep Protein / enzyme biologic — Inhaled

Indications

No indication recorded.